GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the quarter ended June 30, 2026, and provided a business update highlighting progress toward the planned fourth-quarter initiation of its pivotal GEO-MVA immunobridging study under an expedited regulatory pathway established through Scientific Advice discussions with the European Medicines Agency (EMA). The company also continues to advance its Gedeptin immuno-oncology program.
During the second quarter, GeoVax advanced multiple operational initiatives supporting the expected study initiation, including clinical study readiness, manufacturing preparedness using previously manufactured cGMP clinical trial material, and advancement of the AGE1 continuous cell-line manufacturing platform for future commercial-scale MVA vaccine production. The company also engaged with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
David A. Dodd, Chairman and CEO of GeoVax, stated, “During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study. Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GeoVax believes GEO-MVA is uniquely positioned to help address the need for diversified global MVA vaccine manufacturing capacity. The company also continues advancing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
In May 2026, GeoVax announced a strategic reprioritization of its development portfolio to concentrate resources on GEO-MVA and Gedeptin, discontinuing active development of its GEO-CM04S1 COVID-19 vaccine candidate. The decision was based on the evolution and contraction of the global COVID-19 vaccine market and the company’s focus on programs with clearer regulatory pathways and stronger commercialization potential.
Financially, GeoVax reported a net loss of $4,426,578 for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5,369,783, or $8.74 per share, for the same period in 2025. Revenue from government contracts was zero in the 2026 quarter, following the termination of the BARDA contract for the COVID-19 vaccine program in April 2025. Research and development expenses decreased to $3,110,508 from $4,728,998, primarily due to lower costs from discontinued BARDA activities. General and administrative expenses declined to $1,331,564 from $1,542,190. Cash and cash equivalents stood at approximately $3.1 million as of June 30, 2026.
Additional financial details are available in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. For more information about GeoVax and its programs, visit www.geovax.com.
